1044 results about "Nephrosis" patented technology

The invention discloses a peritoneal dialysis anti-blocking high-circulation nursing device for pediatric nephropathy patients, and belongs to the technical field of medical nursing. Comprising the following modules: a multi-mode sensing module for collecting pressure, flow velocity, turbidity, vibration spectrum and temperature data in a catheter in real time; the signal optimization processing module highlights weak features of potential blockage and improves data quality; the feature fusion analysis module is used for comprehensively evaluating the state of the catheter; the AI prediction analysis module is used for predicting the occurrence probability, the position and the possible time window of blockage; the risk early warning and intervention module is used for sending out graded early warning signals according to the prediction result and generating personalized anti-blocking intervention suggestions; the micro-fluidic execution module inhibits formation of initial sediments through a micro-pulse technology and dynamic fluid mechanics adjustment, and effectively reduces the risk of blockage; and the remote medical support module provides visual data visualization and intervention suggestions, supports remote monitoring and emergency intervention, and is seamlessly integrated with a hospital system while ensuring data security.

The invention relates to the field of medical information processing and traditional Chinese medicine curative effect evaluation, in particular to a diabetic nephropathy traditional Chinese medicine curative effect evaluation method based on patient report outcome. The method comprises the following steps: searching related symptoms and clinical characterization data of diabetic nephropathy through a medical database, extracting target entries, performing language standardization processing, constructing an initial candidate entry set, calculating the occurrence frequency of each symptom entry, and screening entries meeting a set threshold value to form an entry set; carrying out dimension division on the entry set according to feature attributes to form a preliminary dimension structure set; forming a screening result set through preset logic screening conditions; and carrying out weighted regression fusion on the comprehensive curative effect score and clinical detection data, and outputting a patient curative effect index. In an item weight determination process, dynamic balance between subjective experience and objective statistical information is realized through a mixed weighting model, and the defects of strong subjectivity of expert scoring and large result fluctuation in a traditional method are overcome.

A class of compounds and the use thereof in a drug. Specifically, the present invention relates to a class of new compounds, a pharmaceutical composition containing the compounds, a method for preparing the compounds, and the use of the compounds or the pharmaceutical composition in the preparation of a drug for treating GLP-1 receptor agonist-mediated diseases and / or disorders, particularly the use in the preparation of a drug for treating diabetes, non-alcoholic fatty liver disease, obesity, myocardial infarction, heart failure, diabetic nephropathy, Parkinson's disease and Alzheimer's disease.

The invention discloses a diabetic nephropathy risk assessment and prediction system based on platelet indexes, and particularly relates to the technical field of disease risk prediction, which comprises a platelet index acquisition module, a drug use data acquisition module, a drug intervention assessment module, an index correction module, a clustering analysis module and a diabetic nephropathy risk assessment module, the method comprises the following steps: acquiring platelet related detection indexes and historical medication data of a patient, calculating a drug intervention influence index and generating a correction factor, realizing platelet index reverse reduction correction by adopting a convolutional neural network model, determining a similar group in combination with clustering analysis, and dynamically evaluating the risk of diabetic nephropathy based on the average morbidity of the group. Personalized accurate prediction is realized; the platelet index correction accuracy is improved, individualized drug intervention elimination is achieved, the similar population clustering analysis precision is enhanced, diabetic nephropathy risk prediction is dynamically adjusted in combination with comprehensive scores, and the early screening and individualized intervention effects are improved.

The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

The invention relates to the technical field of medical health management, in particular to a chronic kidney disease and diabetes collaborative nutrition monitoring and early warning method and system.The method comprises the steps that multi-dimensional physiological indexes, nutrition intake and sleep data of a patient are obtained, and a dynamically-coupled metabolic state topological space is constructed; based on the space, constructing a dual-disease metabolism coupling matrix, analyzing stability characteristics of a metabolism state trajectory, identifying stable and unstable attractors, and calculating a multi-dimensional risk score; a sleep-metabolism synchronism risk prediction model is introduced, and a personalized early warning threshold value is dynamically adjusted; when the risk score exceeds a threshold value, early warning is triggered, and intervention suggestions are generated, the interactive influence of protein metabolism and glycometabolism is quantitatively described from the metabolic mechanism level, and the contradiction of chronic kidney disease and diabetic patients in nutrition management is solved; limitation of a static threshold is broken through, and dynamic risk assessment is realized; sleep factors are creatively integrated, and a new way for improving the metabolic state is provided.

The invention provides a multi-modal kidney pathological picture processing method and device, electronic equipment and a medium. The method comprises the following steps: acquiring an immunofluorescence picture included in a to-be-processed multi-modal kidney pathological picture and a PAS staining pathological picture corresponding to the immunofluorescence picture; inputting the immunofluorescence pictures into a pre-trained first network model to perform nephropathy type classification to obtain nephropathy types; judging whether the nephropathy type output by a pre-trained first network model belongs to a preset nephropathy type or not; inputting a PAS staining pathological picture corresponding to the immunofluorescence picture into a pre-trained second network model for pathological structure identification when the immunofluorescence picture belongs to the preset nephropathy type, and outputting a label for the identified pathological structure; and adding an Oxford typing label to the to-be-processed multi-modal kidney pathological picture based on a label and a pathological structure output by a pre-trained second network model. According to the scheme, the nephropathy type can be automatically distinguished, the Oxford typing label is added, the processing speed is high, and the accuracy rate is high.

The invention discloses a method for constructing a differential diagnosis model for lupus nephritis and membranous nephropathy, and belongs to the technical field of intelligent medical treatment. The modeling method comprises the following steps: S1, respectively collecting flow cytometry detection data of lupus nephritis patients and healthy control personnel; s2, performing data cleaning and conversion on the flow cytometry detection data, and converting non-numerical features into digits; carrying out implication on the missing value by adopting a k nearest neighbor algorithm from an implication packet; s3, random sampling is carried out on the cleaned and converted data set, and samples are divided into a training set and a verification set according to the proportion of 7: 3; s4, dividing a training subset and a test set from the training set, and iteratively selecting the types of cells incorporated into the constructed model as pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T, and CD38 + PD-1 + CD8T by adopting an RFE method, wherein the types of the cells incorporated into the constructed model are pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T and CD38 + PD-1 + CD8T; and S5, performing a classification task by adopting TabPFNClassifier, performing training from features selected from the training data set, then evaluating the performance of the model, performing model training by utilizing detection data, and performing evaluation to construct a lupus nephritis prediction model with high accuracy.

The invention discloses application of oligopeptide in preparation of a medicine for treating and / or preventing diabetic nephropathy. The oligopeptides comprise oligopeptides with the amino acid sequence of SEQ ID NO: 1: LNLYP and derivative sequences or conservative substitution variants of the oligopeptides. The oligopeptide can significantly improve renal function indexes of mice with diabetic nephropathy, such as UACR, serum creatinine, urea nitrogen and the like, enhance podocyte barrier integrity and inhibit accumulation of advanced glycosylation end products AGEs in kidney tissues, and provides a basis for development of novel drugs for treating diabetic nephropathy.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention provides a diabetic nephropathy early warning method, system, equipment and medium, and relates to the technical field of medical data analysis and prediction.The method comprises the steps that multiple urine samples of a user are collected, target urine protein detection is conducted, and multiple urine protein concentrations are obtained; each urine protein concentration is combined with a normal urine protein concentration set to be input into an abnormal data recognition tree, the number of layers of multiple recognition nodes is obtained, and the detection confidence coefficient is obtained through calculation; configuring an abnormal proportion according to the detection confidence coefficient, inputting a plurality of urine protein concentration combination normal urine protein concentration sets into an abnormal data identification tree, deleting urine protein concentrations divided into abnormal data in the abnormal proportion before, and obtaining screened urine protein concentrations; according to the screened urine protein concentration, an auxiliary early warning coefficient is obtained through calculation, and early warning is carried out. The technical problem of low early warning accuracy of diabetic nephropathy in the prior art is solved.

The invention discloses a biomarker for nephrotic syndrome, an analysis method and a kit, which can be effectively used for diagnosis of nephrotic syndrome and have high sensitivity and accurate and reliable results. The biomarker for nephrotic syndrome comprises the mRNA, the protein and the enzymatic activity level of the following substances: lactate dehydrogenase B.

The invention relates to a flavonoid active fraction of an Abelmoschi corolla, a preparation method and an application thereof, and belongs to the field of traditional Chinese pharmaceutics. A high-purity Abelmoschi corolla flavonoid active fraction is prepared, which is found to have better therapeutic activity for kidney disease, and especially have a significant therapeutic effect for diabetic kidney disease and lupus nephritis, or contrast-induced kidney injury and eye diseases. Meanwhile, the Abelmoschi corolla flavonoid active fraction described in the invention also has good safety.

The present invention belongs to the field of probiotic fermentation technology, and specifically relates to a fermented product of Bifidobacterium longum subsp. infantis, and a preparation method thereof, and applications thereof in improving testosterone levels and fertilization rates, improving chronic kidney disease, and combating fatigue. The Bifidobacterium longum subsp. infantis NKU FB3-14 composition of the present invention and a probiotic fermented product prepared using the Bifidobacterium longum subsp. infantis NKU FB3-14 composition as a raw material have bioactive substances that are different from the raw materials, thereby achieving the effects of improving testosterone levels and fertilization rates, improving chronic kidney disease, and combating fatigue.

The invention belongs to the technical field of biological medicines, and particularly relates to application of poecilobdella manillensis in preparation of a medicine for treating renal injury. The invention provides a new application of poecilobdella manillensis in preparation of a medicine for treating renal injury, serum biochemical index detection proves that the poecilobdella manillensis can effectively reduce serum creatinine and blood urea nitrogen levels, increase serum albumin and total protein content, remarkably improve glomerular filtration function and protein metabolism function, and improve renal function. And the improvement degree of the traditional Chinese medicine composition is superior to that of a traditional Chinese medicine contrast. Although the curative effect is slightly poorer than that of a chemical drug group, the safety advantage is remarkable. The poecilobdella manillensis can comprehensively regulate renal function metabolism indexes, relieve kidney injury and avoid common side effects of chemical drugs, provides a new choice for clinical treatment of kidney injury, and is especially suitable for chronic kidney disease patients needing long-term treatment.

The present invention discloses a culture medium, a fermentation method and an application of Streptomyces for producing pieridian glycosides. Through this fermentation method, the Streptomyces can produce abundant pieridian glycosides, and its effective part contains more than 8 types of pieridian glycosides at the same time, and the content of the four types of pieridian glycosides, namely compound 4, compound 5, compound 6 and compound 8, is greater than 5%. The extract obtained by the strain through this fermentation method and its effective part can be used to prepare drug lead compounds for treating renal cancer, organ fibrosis, acute kidney injury and chronic kidney disease, and can provide drug source guarantee for China's marine drug research and development.

The invention relates to the technical field of medical artificial intelligence and chronic kidney disease management crossing, in particular to a nonlinear algorithm system for precise chronic disease management of chronic kidney diseases. Through deep coupling of algorithms and in combination with two exclusive quantification formulas, transformation of CKD chronic disease management from standardized follow-up visit to precise and dynamic algorithm driving is realized, and the core pain points of large staging evaluation deviation, progress pre-judgment lag, poor intervention scheme adaptability, follow-up visit strategy homogenization and the like in traditional CKD management are solved. The method provides full-cycle decision support for nephrology doctors in the three-A hospital, customizes an individualized chronic disease management path for CKD patients, is suitable for CKD 1-5 period full-staging patients, and can be widely applied to CKD special management scenes of chronic disease diagnosis and treatment centers in the nephrology department of the three-A hospital, chronic disease management outpatient clinics in special nephropathy hospitals and high-end health management institutions.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The invention discloses a method and system for predicting membranous nephropathy based on machine learning, and relates to the technical field of medical diagnosis and treatment, and the method comprises the steps: collecting multi-source heterogeneous data of a patient; preprocessing the multi-source heterogeneous data, constructing a mapping relation between the traditional Chinese medicine syndrome type and the molecular biomarker, and generating a traditional Chinese and western medicine fusion feature matrix; screening a feature subset related to membranous nephropathy prediction from the traditional Chinese and western medicine fusion feature matrix; constructing a membranous nephropathy multi-level prediction framework according to the feature subset, and training each prediction model in the framework; and applying the trained and optimized membranous nephropathy multi-level prediction framework to the feature subset data of the new patient to generate a membranous nephropathy multi-dimensional prediction result. By establishing the Chinese and western medicine feature mapping relation, deep fusion of traditional Chinese medicine diagnosis and modern medical indexes is realized, and comprehensiveness and accuracy of disease diagnosis are improved.

The invention discloses a diabetic nephropathy patient retinopathy image classification method based on artificial intelligence, and relates to the technical field of medical images, and the method comprises the steps: collecting a retina image, carrying out the denoising and contrast adjustment, and generating a standardized image; carrying out feature constraint by utilizing a generative adversarial network guided by medical priori knowledge in combination with microaneurysm morphology and bleeding area texture features, generating a retina image with enhanced pathological features, and constructing an amplification training data set; training a deep convolutional neural network based on the data set, identifying microaneurysm and bleeding lesion by using a multi-scale feature extraction layer, and outputting a preliminary classification result; and a reinforcement learning environment is constructed in combination with clinician feedback, and a classification decision threshold is dynamically adjusted to optimize lesion grading parameters. According to the method, cross-modal correlation analysis is adopted, retinopathy features and biochemical time sequence data are fused, and the accurate classification capacity of diabetic retinopathy images is improved.

The present disclosure relates to flavor compositions and pet food products for preventing and / or treating chronic kidney disease (CKD) and / or urinary tract disease in an animal. In certain embodiments, the flavor compositions and pet food products have enhanced palatability.

The present invention relates to a compound for inducing the expression of the anti-aging gene klotho and a preparation method therefor. The compound represented by Chemical Formula 1, according to the present invention, has an excellent effect of increasing the expression level of the klotho gene which is a gene associated with aging, and thus can be useful for a pharmaceutical composition, cosmetic composition or food composition for preventing skin aging, inhibiting cellular senescence or preventing, treating alleviating a vascular aging-induced disease or a renal disease.

The invention discloses a preparation method and application of a medicinal and edible traditional Chinese medicine compound with an effect of treating uric acid diseases. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 to 25 parts of semen plantaginis, 15 to 25 parts of pawpaw, 5 to 15 parts of rhizoma smilacis glabrae, 5 to 15 parts of herba portulacae, 1 to 11 parts of radix glycyrrhizae preparata, 5 to 15 parts of folium mori, 5 to 15 parts of folium perillae, 1 to 11 parts of semen pruni, 5 to 15 parts of rhizoma polygonati, 1 to 11 parts of black dates and 1 to 9 parts of mulberries. The traditional Chinese medicine compound is composed of medicinal and edible raw materials, has stable efficacy of reducing uric acid and relieving uric acid liver and kidney injury, renal fibrosis and gouty arthritis, can relieve arthrocele caused by gout, reduces the level of joint inflammatory factors and the like, and takes effect quickly. The traditional Chinese medicine composition can be used for treating hyperuricemia, uric acid nephropathy, gouty arthritis and hyperuricemia accompanying symptoms.

The present invention belongs to the field of traditional Chinese medicines, and particularly relates to Leixihaokang, a preparation method therefor, and use thereof. The Leixihaokang of the present invention is prepared from the following active pharmaceutical ingredients in parts by weight: 10 parts of Tripterygium glycosides and 0.1-1.3 parts of Artemisia annua extract. According to the present invention, animal experiments prove that the Leixihaokang can ameliorate renal damage in nephrotic syndrome caused by adriamycin, reduce the occurrence of proteinuria, and reduce the apoptosis of renal tissue cells. Meanwhile, the Leixihaokang of the present invention has a good inhibitory effect on renal, hepatic, splenic, and cardiac toxicity in the treatment process of nephrotic syndrome. According to the present invention, animal experiments also prove that the Leixihaokang can ameliorate skin injury in imiquimod-induced psoriasis, reduce inflammatory infiltration and alleviate skin damage. Meanwhile, the Leixihaokang has a certain degree of inhibitory effect on the hepatic and reproductive system toxicity in the treatment process of psoriasis.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.

The invention relates to a deep learning-based early-stage amyloidosis nephropathy identification and diagnosis method, belongs to the technical field of amyloidosis nephropathy identification, and solves the problem that early-stage amyloidosis cannot be accurately identified in the prior art. The method comprises the following steps: acquiring kidney pathological section images of different individuals to construct a training sample set; constructing a link model comprising a first region segmentation model, a second region segmentation model and a third region segmentation model; the first region segmentation model is used for segmenting a cortex region in the pathological image; the second region segmentation model is used for segmenting a glomerular region; the third region segmentation model is used for identifying amyloidosis of a glomerular region; training the link model based on the training sample set to obtain a trained link model; and inputting a to-be-identified kidney pathological section image into the trained link model to identify whether amyloidosis exists or not. And efficient and accurate early-stage amyloidosis identification is realized.

The utility model provides a bioreactor device for replacing the function of a renal tubule, the bioreactor device is placed in a cell culture incubator, the bioreactor device comprises a fixed frame and a chip, the chip is arranged on the fixed frame, and a vein-imitated renal tubule structure is formed in the chip; openings in the two ends of the flow channel are respectively a liquid inlet and a liquid outlet; the inner diameter of the main flow channel is larger than that of the micro flow channel; wherein the inner diameter of the main flow channel and the inner diameter of the micro flow channel of the chip are both within the pipe diameter range of the physiological renal tubule; a human renal tubular epithelial cell suspension enters the vein-imitating flow channel from the liquid inlet and is attached to the inner wall of the vein-imitating flow channel. Therefore, the structure of the renal tubule is reflected in a more bionic and more reasonable manner, the physiological environment of the renal tubule can be simulated more accurately, a new design thought and method are provided for a renal tubule bioreactor device in a bioartificial kidney, the difficulty in the field of kidney replacement therapy is expected to be solved, and the life quality of patients with end-stage renal failure due to nephropathy is improved.

The invention discloses a nephropathy auxiliary diagnosis decision-making method and system based on artificial intelligence, and relates to the technical field of nephropathy auxiliary diagnosis, and the method comprises the steps: extracting the multi-dimensional features of nephropathy according to the nephropathy detection type, and building a nephropathy feature data set; determining importance rates of different clinical index types; establishing a nephropathy diagnosis model based on a grey theory objective evaluation algorithm; comprehensively judging whether the nephropathy detection model has credibility and reliability or not; collecting clinical detection data of a patient, and establishing a nephropathy detection data set; and determining a comprehensive nephropathy diagnosis result of the patient and generating a nephropathy diagnosis sheet. The method has the advantages that key diagnosis features are effectively extracted through principal component analysis dimensionality reduction and multi-dimensional feature analysis, the limitation that a traditional method depends on a single index is solved, the deviation degree of patient data and health benchmark is quantified through grey theory correlation analysis, and doctors can visually understand model auxiliary diagnosis decision logic.

The invention discloses an application of ARN2966 in the treatment of UMOD (Urban Molecular Orthodontic Disease) gene mutant autosomal dominant hereditary renal tubular interstitial nephropathy (ADTKD), and belongs to the field of biomedicine. The ARN2966 has the advantages that the ARN2966 can be used for the treatment of UMOD gene mutant autosomal dominant hereditary ADTKD, and the ARN2966 can be used for the treatment of UMOD gene mutant autosomal dominant hereditary ADTKD; the application comprises the application of the amyloid precursor protein (APP)-CD74 signal axis blocking agent in the preparation of the medicine for treating the hereditary tubulointerstitial nephropathy, and the application comprises the application of the amyloid precursor protein (APP)-CD74 signal axis blocking agent in the preparation of the medicine for treating the hereditary tubulointerstitial nephropathy. Compared with the prior art, the key effect of an APP-CD74 signal axis in ADTKD-Umod pathogenesis is disclosed for the first time, and ARN2966 provides a brand new intervention strategy for treatment of ADTKD-Umod through targeted regulation and control of the pathway. Compared with a broad-spectrum anti-inflammatory drug, the ARN2966 has high targeting specificity, and side effects caused by non-specific immunosuppression can be avoided. Although the ARN2966 does not enter a clinical research stage at present, due to the unique action mechanism and verified safety characteristics of the ARN2966, the ARN2966 has remarkable transformation medical value and clinical application prospect in the aspect of developing ADTKD-Umod targeted therapeutic drugs.